Aliases:This biomarker is also known as:
- secretory leukocyte peptidase inhibitor,
- Mucus proteinase inhibitor,
- WAP four-disulfide core domain protein 4,
- Seminal proteinase inhibitor,
- secretory leukocyte protease inhibitor (antileukoproteinase),
SLPI is a secreted inhibitor which protects epithelial tissues from serine proteases. It is found in various secretions including seminal plasma, cervical mucus, and bronchial secretions, and has affinity for trypsin, leukocyte elastase, and cathepsin G. Its inhibitory effect contributes to the immune response by protecting epithelial surfaces from attack by endogenous proteolytic enzymes; the protein is also thought to have broad-spectrum anti-biotic activity.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Overexpression of SLPI has been measured in invasive and low malignant potential tumors compared with benign and normal tissues.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. SLPI alone was not a strong predictor.
|QA State:||Under Review|
- Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
- Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.
- A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.